Brief: Galectin Therapeutics Reports Financial Results For The Quarter Ended September 30, 2022 And Provides Business Update
14/11/2022 18:09
Nov 14 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS INC QUARTERLY LOSS PER SHARE $0.14
* GALECTIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE
QUARTER
ENDED SEPTEMBER 30, 2022 AND PROVIDES BUSINESS UPDATE
* GALECTIN THERAPEUTICS INC - AS OF SEPTEMBER 30, 2022,
COMPANY
HAD $15.8 MILLION OF CASH AND CASH EQUIVALENTS
* GALECTIN THERAPEUTICS- BELIEVES HAS SUFFICIENT CASH TO
FUND
CURRENTLY PLANNED OPERATIONS AND RESEARCH AND DEVELOPMENT
ACTIVITIES THROUGH AT LEAST DEC 31, 2024
Source text for Eikon: ID:nGNX7nmTjh
Further company coverage: GALT.O
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study